TYRA/ 04/06/2026 · 7:00 AM Tyra Biosciences Receives Buy Rating – Key 2026 Data Ahead Tyra Biosciences’ dabogratinib shows promise: works well for bladder cancer & dwarfism with fewer side effects. Big 2026 trials ahead.
